Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]